
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">







<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>


<P>
<HR noshade width="26%" align="center" size="1">
<P>



<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF<BR>
THE SECURITIES EXCHANGE ACT OF 1934



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) DECEMBER 17, 2004



<P>
<HR noshade width="26%" align="center" size="1">
<P>



<P align="center" style="font-size: 24pt"><B>NORTHWEST BIOTHERAPEUTICS, INC.</B>


<DIV align="center" style="font-size: 10pt">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
</DIV>


<P>
<HR noshade width="26%" align="center" size="1">
<P>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="33%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><B>DELAWARE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>0-33393</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>94-3306718</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center">(STATE OR OTHER JURISDICTION</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">(COMMISSION FILE</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">(I.R.S. EMPLOYER</TD>
</TR>

<TR valign="bottom">
    <TD align="center">OF INCORPORATION)</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">NUMBER)</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IDENTIFICATION NO.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">22322 20th Avenue SE, Suite&nbsp;150, Bothell, WA 98021<BR>
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">REGISTRANT&#146;S TELEPHONE NUMBER, INCLUDING AREA CODE (425)&nbsp;608-3000



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">INAPPLICABLE<BR>
(FORMER NAME OR FORMER ADDRESS IF CHANGED SINCE LAST REPORT)



<P>
<HR noshade width="26%" align="center" size="1">
<P>



<P align="left" style="font-size: 10pt">Check the appropriate box
below if the Form&nbsp;8-K is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the
Securities Act (17&nbsp;CFR&nbsp;230.425)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the
Exchange Act (17&nbsp;CFR&nbsp;240.14a-12)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to
Rule&nbsp;14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to
Rule&nbsp;13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</TD>
</TR>
</TABLE>
</DIV>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;8.01 Other Events.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURE</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.</B>


<P align="left" style="font-size: 10pt">Northwest Biotherapeutics, Inc. (the &#147;Company&#148;) announced today that, on December&nbsp;17, 2004, Dr.
Randall&nbsp;L-W. Caudill and Mr.&nbsp;Wayne&nbsp;L. Pines resigned as directors of the Company as anticipated by
the Company in connection with the Amended and Restated Recapitalization Agreement. Their
resignations leave the Company with one remaining director,
Alton&nbsp;L. Boynton,&nbsp;Ph.D., who is also
the Company&#146;s President. The Company is party to an Amended and Restated Recapitalization
Agreement with Toucan Capital Fund&nbsp;II. The Amended and Restated Recapitalization Agreement
contemplates an operational and capital restructuring of the Company. The changes are contemplated
to occur over two periods, a bridge period, which commenced in February, and an equity financing
period. Over the course of the bridge period the Company has received loans from Toucan in
aggregate of $4.1&nbsp;million to date. The commencement of the equity financing period will occur upon the
first closing of a sale of preferred stock to Toucan and, at Toucan's
election, other investors selected by Toucan and
will last for up to 12&nbsp;months. As part of its Amended and Restated Recapitalization Agreement, the
Company agreed to a reconstitution of its board of directors in connection with the issuance of the
preferred stock. The resignations of Dr.&nbsp;Caudill and Mr.&nbsp;Pines were submitted with the knowledge
that the Company&#146;s stockholders had approved the proposals necessary for the Company to proceed
with a potential private placement of up to $40&nbsp;million with Toucan and other investors selected by
Toucan should Toucan elect to purchase the Company&#146;s stock.


<!-- link2 "Item&nbsp;8.01 Other Events." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>


<P align="left" style="font-size: 10pt">The Company also announced today that it held its annual meeting of stockholders on December&nbsp;17,
2004. There were five proposals submitted to stockholders for their approval. The proposals
included: (i)&nbsp;approval of the terms of a potential private placement of up to $40&nbsp;million of the
Company&#146;s preferred stock; (ii)&nbsp;approval of an amendment to the Company&#146;s sixth amended and
restated certificate of incorporation to effect a reverse stock split of not less than 1-for-15 and
not more than 1-for-60, with the Company&#146;s board of directors having authority to determine which,
if any, of these reverse stock splits to effect within those parameters; (iii)&nbsp;approval of an
amendment to the Company&#146;s sixth amended and restated certificate of incorporation to increase the
Company&#146;s authorized capital stock from 140,000,000&nbsp;shares
to 400,000,000&nbsp;shares, consisting of
300,000,000 shares of common stock and 100,000,000 shares of preferred stock; (iv)&nbsp;election of one
director to the Company&#146;s board of directors to serve until the 2007 Annual Meeting of Stockholders
and until his successor has been elected and qualified (or his earlier resignation or removal); and
(v)&nbsp;ratification of the appointment of KPMG LLP as the Company&#146;s independent auditors for the
fiscal year ending December&nbsp;31, 2004.


<P align="left" style="font-size: 10pt">All proposals were approved by the requisite number of the outstanding shares of the Company&#146;s
capital stock.




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt">SIGNATURE


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="2"><B>NORTHWEST BIOTHERAPEUTICS, INC.</B></TD>
</TR>


<TR style="font-size: 20pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="2">&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>

    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD align="left" valign="top">/s/ Alton, L. Boynton</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alton, L. Boynton<BR>
President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt">Dated:
December&nbsp;22, 2004



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

